Journal of Analytical Toxicology Publishes Peer-Reviewed Validation Study Demonstrating Accuracy of Omega Laboratories' Test Method for Detecting Marijuana in Breath Samples Using Cannabix Technologies' Breath Collection Unit

Executive Summary

• Omega Laboratories and Cannabix Technologies announced the peer‑reviewed publication of a validation study in Journal of Analytical Toxicology confirming the accuracy of Omega’s breath‑based cannabinoid detection method using Cannabix’s Breath Collection Unit (BCU).
• The study demonstrates simultaneous quantification of Δ9‑THC, Δ8‑THC, CBD and CBN in breath aerosols with a detection window of up to 4 hours, establishing the BCU as a commercially viable tool for recent cannabis use testing.
• Both companies highlight forward‑looking plans to scale manufacturing of the BCU and collection kits, positioning the technology for workplace safety, law‑enforcement, and road‑safety applications.

Key Details

• Publication: “Simultaneous Analysis of Δ9‑THC, Δ8‑THC, CBD, and CBN in Breath Aerosols Collected Using Cannabix Technologies Breath Collection Unit,” Journal of Analytical Toxicology (Oxford University Press). DOI: https://doi.org/10.1093/jat/bkag016
• Validation Highlights:
• Simultaneous quantification of four cannabinoids (Δ9‑THC, Δ8‑THC, CBD, CBN) in breath samples.
• Improved detection sensitivity and precision versus prior methods.
• Sample stability demonstrated for up to 7 days in the Cannabix Breath Collection Kit.
• Correlation of THC concentration‑time trends in breath with established blood data.
• Testing Protocol:
• Dual “A & B” cartridge system; A sample screened by LC‑MS/MS, B sample tested if A is presumptively positive; ambient air sample analyzed when both are positive to rule out environmental contamination.
• Detection window: 15 minutes to 4 hours post‑consumption.
• Strategic Partnership: Initiated May 2024; Cannabix performed design enhancements on the BCU, Omega refined laboratory methodology over a 20‑month period.
• Manufacturing Ramp‑Up: Cannabix is increasing production capacity for BCU units and Breath Collection Kits to meet anticipated demand in safety‑sensitive markets.
• Market Applications: Workplace drug testing, law‑enforcement roadside investigations, clinical settings, and drug‑treatment facilities seeking a non‑invasive, recent‑use detection method.
• Forward‑Looking Statements: Companies anticipate broader adoption, regulatory acceptance, and commercial scaling of the breath‑based THC testing solution; risks include scientific replication, regulatory hurdles, supply‑chain constraints, and market competition.

Notable Quotes

• “This new publication reinforces the effectiveness of using breath to detect recent drug use,” – Bill Corl, CEO, Omega Laboratories.
• “The peer‑reviewed article publication … is a significant milestone for Cannabix and its shareholders,” – Rav Mlait, CEO, Cannabix Technologies.